Dow Jones
31.880,24 +618,34 (+1,98%) Nasdaq
11.535,27 +180,66 (+1,59%) Nikkei 225
26.911,04 -90,48 (-0,34%) EUR/USD
1,0677 -0,0019 (-0,18%) BTC-EUR
27.379,03 -1.160,12 (-4,06%) CMC Crypto 200
654,67 -20,21 (-2,99%)
BioMarin Pharmaceutical Inc. (0HNC.L)
| Chiusura precedente | 78,73 |
| Aperto | 80,56 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 80,56 - 80,56 |
| Intervallo di 52 settimane | 80,56 - 80,56 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 14,672B |
| Beta (5 anni mensile) | 0,41 |
| Rapporto PE (ttm) | 374,70 |
| EPS (ttm) | 0,22 |
| Prossima data utili | 26 lug 2022 - 01 ago 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
BMRN FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December 22, 2021 lead plaintiff deadline. SO WHAT: If you purchased BioMarin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline – BMRN
NEW YORK, Dec. 19, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities bet
- GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December 22, 2021 lead plaintiff deadline. SO WHAT: If you purchased BioMarin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen
